Background:About 1 in 10 adults have breathlessness, totalling over 1.8 million in Australia alone.Breathlessness (dyspnoea) is a common presenting complaint in primary care and is a symptom of cardiovascular and respiratory disease, but also associated with obesity, loss of fitness and anxiety.Breathlessness that chronically limits exertion significantly reduces quality of life and is becoming more prevalent following bushfires, consequent worsening air pollution and severe SARS-CoV-2 pandemic. Respiratory conditions account for around 10% of deaths in Australia and 31% of Australian adults have a chronic respiratory disease. There is a significant need to improve health outcomes in respiratory space, however the multifactorial nature of breathlessness challenges general practitioners’ ability to provide correct diagnosis or best management. In a recent survey of over 10,000 Australian adults, 22% reported a current respiratory or heart condition or both. Of those with a current respiratory condi

Hosted by The George Institute India, in partnership with Imperial College London, the NIHR Global Health Research Centre for Non-Communicable Diseases and Environmental Change aims to be a recognised centre of excellence on non-communicable diseases (NCDs) and global environmental change in low and middle-income countries (LMICs), offering world-leading research, training and policy advice for health equity. LMICs face dual, intertwined challenges of a rapidly growing burden of NCDs and the existential threat of global environmental change. In addition, health systems in LMICs face specific challenges in delivering high-quality, equitable services for NCDs prevention and care, especially for marginalised populations most impacted by environmental change.Despite an increasingly recognised imperative for action, there is a paucity of evidence on cost-effective interventions to address major challenges emerging at the nexus of NCDs and environmental change.Our Centre will focus on Bangladesh, India, and Indones

BackgroundAcute kidney injury (AKI) is caused by a loss of kidney function. This leaves the body unable to remove waste products, and balance water and electrolyte levels effectively. Some people with AKI may experience it short-term and recover their kidney function. For others, AKI may progress further and develop into chronic kidney disease (CKD), especially for those who have other co-existing conditions that require treatment. People who have recovered from AKI, however, have an increased risk of other health problems or even having AKI again in the future.A new class of oral anti-hyperglycaemic drugs, called sodium glucose co-transporter 2 (SGLT2) inhibitors, were initially used in the treatment of T2DM. They work by increasing the removal of glucose, and in turn lowering blood glucose levels.There is now a growing amount of research evidence to show SGLT2 inhibitors have additional benefits in people who are at risk of cardiovascular and kidney disease. SGLT2 inhibitors have been shown t

The Blood In Action project will work with the community and experts in infection and pregnancy to make use of thousands of blood samples provided by women during their maternity care to examine how diseases transmit from person to person. Blood samples of pregnant women receiving NHS pregnancy care are stored for two years in case of suspected exposure to infection in the mother or baby. These samples can be tested for existing antibodies (a marker of immunity) and linked to information about age, ethnicity, and deprivation, to build a picture of the impact of infections on women, children, and the general population. They are otherwise thrown away at 2 years. During the COVID-19 pandemic, the research team comprising colleagues from the George Institute for Global Health, UK, Imperial College London, and the Imperial College Healthcare NHS Trust used these samples to map the spread of the virus in North-West London, over time and in different groups of women. This 3-year project will extend this wo